Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

NEUROMETRIX, INC.

(NURO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

NeuroMetrix : Announces Peer-Reviewed Publication of a Randomized Controlled Trial of its Wearable Neurostimulation Technology for Treatment of Fibromyalgia

07/26/2021 | 09:01am EDT

WOBURN, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced a publication titled “Effects of Wearable Transcutaneous Electrical Nerve Stimulation on Fibromyalgia: A Randomized Controlled Trial" in the Journal of Pain Research. The article is available online at the journal website.

The article reports an intention-to-treat analysis of a double-blind, randomized, sham-controlled trial that compared 3-months of at-home treatment with a standard (active) or low dose (sham) Quell device in 119 subjects with fibromyalgia.

Note: The use of Quell for fibromyalgia is investigational and has not been cleared or approved by the U.S. Food and Drug Administration (FDA).

About Fibromyalgia

Fibromyalgia is a common form of chronic pain that is also accompanied by fatigue, sleep, cognitive and mood disturbances. It affects an estimated 2 to 6 percent of the U.S. population (5 to 15 million people) and is most often diagnosed between the ages of 30 and 50. The cause of fibromyalgia remains unclear, but scientific studies point to abnormalities in the way the brain processes normal sensations and pain. Although several drugs are FDA approved for managing fibromyalgia pain, there is an unmet need for safe and effective non-pharmacological treatments.

About Quell

Quell is an advanced, non-invasive, nerve stimulation device that is covered by 18 U.S. utility patents. It is the only wearable neurostimulator that is enabled by a custom designed microchip that provides precise, high-power nerve stimulation in a form factor the size of a credit card. Quell utilizes position and motion sensing to automatically adjust stimulation for an optimal patient experience both day and night. The device supports Bluetooth® low energy (BLE) to communicate with the Quell app, which is available for iOS and Android mobile devices. Quell is currently indicated for symptomatic relief and management of chronic lower extremity (knee, foot and leg) pain. It is available over-the-counter for this use. Visit QuellRelief.com for more information.

About NeuroMetrix

NeuroMetrix is an innovation-driven company focused on the development and global commercialization of non-invasive medical devices for the diagnosis and treatment of pain and neurological disorders. The Company has three commercial products. DPNCheck® is a diagnostic device that provides rapid, point-of-care detection of peripheral neuropathies. ADVANCE® is a diagnostic device that provides automated, in-office nerve conduction studies for the evaluation of entrapment neuropathies. Quell® is a wearable neurostimulation device indicated for treatment of lower extremity chronic pain. For more information, visit www.NeuroMetrix.com.

Source: NeuroMetrix, Inc.

Thomas T. Higgins
SVP and Chief Financial Officer
781-314-2761
neurometrix.ir@neurometrix.com


Primary Logo

Source: NeuroMetrix, Inc.

2021 GlobeNewswire, Inc., source Press Releases

All news about NEUROMETRIX, INC.
08/27Top Premarket Gainers
MT
08/13INSIDER TRENDS : Insider Sale at NeuroMetrix Scaling Back 90-Days of Buying
MT
08/13NEUROMETRIX : Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (included in ..
PU
08/13NEUROMETRIX, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
07/26NEUROMETRIX : Announces Peer-Reviewed Publication of a Randomized Controlled Trial of its ..
AQ
07/22NEUROMETRIX : Q2 Loss Narrows as Revenue Climbs
MT
07/22NEUROMETRIX : Management's Discussion and Analysis of Financial Condition and Results of O..
AQ
07/22Wall Street Wavers Pre-Bell as Jobless Claims Rise
MT
07/22Top Pre-Market Gainers
MT
07/22NEUROMETRIX : Reports Q2 2021 Financial Results (Form 8-K)
PU
More news
Financials (USD)
Sales 2020 7,38 M - -
Net income 2020 -2,09 M - -
Net cash 2020 4,17 M - -
P/E ratio 2020 -4,55x
Yield 2020 -
Capitalization 74,6 M 74,6 M -
EV / Sales 2019 0,28x
EV / Sales 2020 1,06x
Nbr of Employees 20
Free-Float 99,4%
Chart NEUROMETRIX, INC.
Duration : Period :
NeuroMetrix, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NEUROMETRIX, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Managers and Directors
Shai N. Gozani Chairman, President & Chief Executive Officer
Thomas T. Higgins Chief Financial Officer, Treasurer & Senior VP
David E. Goodman Independent Director
Nancy E. Katz Independent Director
David van Avermaete Independent Director
Sector and Competitors
1st jan.Capi. (M$)
NEUROMETRIX, INC.319.62%75
ABBOTT LABORATORIES14.28%221 833
MEDTRONIC PLC9.13%172 048
BECTON, DICKINSON AND COMPANY3.51%74 382
HOYA CORPORATION29.05%62 177
SARTORIUS STEDIM BIOTECH84.00%57 875